Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants
Shabir A. Madhi(South African Medical Research Council), Peter Dull(Novartis (United States)), Alaine Izu(University of the Witwatersrand), Ziyaad Dangor(South African Medical Research Council), Ajoke Sobanjo-ter Meulen(Bill & Melinda Gates Foundation), Stephanie J. Schrag(Centers for Disease Control and Prevention), Paul T. Heath(St George's, University of London)
Cited by 132
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
|Cell|2022|1k